This trial will test the safety of a new drug for people who have had a heart attack.
1 Primary · 4 Secondary · Reporting Duration: Day 1 (Baseline/Screening) visit, Day 40 and Day 365
Experimental Treatment
23 Total Participants · 1 Treatment Group
Primary Treatment: PEP in Acute Myocardial Infarction · No Placebo Group · Phase 1
Age 21 - 85 · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: